UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

S168: ERYTHROPOIETIN STIMULATION AGENTS SIGNIFICANTLY IMPROVES OUTCOME IN LOWER RISK MDS

HemaSphere, 2022-06, Vol.6, p.69-70

2022

Volltextzugriff (PDF)

Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation

Leukemia, 2014-02, Vol.28 (2), p.411-413

2014

Volltextzugriff (PDF)

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

Blood, 2019-03, Vol.133 (10), p.1020-1030

2019

Volltextzugriff (PDF)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells

Leukemia, 2010-04, Vol.24 (4), p.756-764

2010

Volltextzugriff (PDF)

Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia

Leukemia, 2010-05, Vol.24 (5), p.1062-1065

2010

Volltextzugriff (PDF)

Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells

Leukemia, 1999-05, Vol.13 (5), p.719-728

1999

Volltextzugriff (PDF)

Myelodysplastic syndromes: biology and treatment

Journal of internal medicine, 2009-03, Vol.265 (3), p.307-328

2009

Volltextzugriff (PDF)

The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts

Leukemia, 2013-04, Vol.27 (4), p.889-896

2013

Volltextzugriff (PDF)

Erythropoiesis‐stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower‐risk myelodysplastic syndrome

Journal of internal medicine, 2017-03, Vol.281 (3), p.284-299

2017

Volltextzugriff (PDF)

The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro

Leukemia, 2001-08, Vol.15 (8), p.1240-1247

2001

Volltextzugriff (PDF)

Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level

Blood, 2000-09, Vol.96 (6), p.2012-2021

2000

Volltextzugriff (PDF)

TARGETING DYSERYTHROPOIESIS IN CLINICAL PRACTICE

LEUKEMIA RESEARCH, 2023-05, Vol.128, p.107093, Article 107093

Hellstrom-Lindberg, E.

2023

Volltextzugriff (PDF)

Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia

Leukemia, 2010-05, Vol.24 (5), p.932-941

2010

Volltextzugriff (PDF)

37 Low-risk MDS; transfusion therapy, growth factors and the European view on lenalidomide

Leukemia research, 2009-05, Vol.33, p.S26-S27

Hellström-Lindberg, E

2009

Volltextzugriff (PDF)

Identification of Aberrant Splicing Events in Myelodysplastic Syndrome Patients with Splicing Factor Gene Mutations

Leukemia research, 2017-04, Vol.55, p.S9-S9

2017

Volltextzugriff (PDF)

Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34 blasts in myelodysplastic syndrome

Leukemia, 2010-09, Vol.24 (9), p.1607-1616

2010

Volltextzugriff (PDF)

165 RECURRENT MUTATIONS AS WELL AS CLONAL EVOLUTION ARE COMMON IN PATIENTS WITH LOWER-RISK MDS AND DEL(5Q) TREATED WITH LENALIDOMIDE

Leukemia research, 2015-04, Vol.39, p.S84-S84

2015

Volltextzugriff (PDF)

217 DEFINING LIKELIHOOD OF FUTURE RESPONSE IN PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE

Leukemia research, 2015-04, Vol.39, p.S109-S109

2015

Volltextzugriff (PDF)

IVA.2 Managing myelodysplastic syndromes in the frail elderly

Critical reviews in oncology/hematology, 2007-11, Vol.64, p.S16-S16

Hellström-Lindberg, E

2007

Volltextzugriff (PDF)

Health-Related Quality of Life is Substantially Impaired in Lower-Risk MDS when Compared with Reference Populations and Significantly Affects Overall Survival

Leukemia research, 2017-04, Vol.55, p.S12-S12

2017

Volltextzugriff (PDF)

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Blood, 2009-07, Vol.114 (5), p.937-951

2009

Volltextzugriff (PDF)

135 IN VITRO AZACITIDINE CULTURE INDUCES DNA DEMETHYLATION AND INCREASED MRNA-LEVELS IN PRIMARY MDS PROGENITOR CELLS

Leukemia research, 2015-04, Vol.39, p.S69-S69

2015

Volltextzugriff (PDF)

Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome

Nature cell biology, 2022-03, Vol.24 (3), p.299-306

2022

Volltextzugriff (PDF)

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

Blood cancer journal (New York), 2014-03, Vol.4 (3), p.e189-e189

2014

Volltextzugriff (PDF)

1 – 25 von 516

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(506)
Mit Volltextzugriff
(474)

Publikationsform

Artikel
(390)
Tagungsberichte
(126)

Sprache

Englisch
(515)
Schwedisch
(2)

Erscheinungsjahr

n.n

Thema

Medicin Och Hälsovetenskap
(402)
Science & Technology
(221)
Life Sciences & Biomedicine
(215)
Humans
(204)
Hematology
(161)
Aged
(89)
Male
(89)
Female
(88)
Middle Aged
(85)
Oncology
(85)
Biological And Medical Sciences
(74)
Medical Sciences
(73)
Myelodysplastic Syndromes - Genetics
(72)
Aged, 80 And Over
(67)
Myelodysplastic Syndromes
(63)
Hematology, Oncology And Palliative Medicine
(59)
Hematologic And Hematopoietic Diseases
(58)
Adult
(57)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(56)
Myelodysplastic Syndromes - Drug Therapy
(51)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

S168: ERYTHROPOIETIN STIMULATION AGENTS SIGNIFICANTLY IMPROVES OUTCOME IN LOWER RISK MDS

Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation

S167: PREDICTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION USING INDIVIDUALIZED MEASURABLE RESIDUAL DISEASE MARKERS; THE PROSPECTIVE NORDIC STUDY NMDSG14B

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells

Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia

Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells

Myelodysplastic syndromes: biology and treatment

The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts

Erythropoiesis‐stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower‐risk myelodysplastic syndrome

The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro

Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level

TARGETING DYSERYTHROPOIESIS IN CLINICAL PRACTICE

Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia

37 Low-risk MDS; transfusion therapy, growth factors and the European view on lenalidomide

Identification of Aberrant Splicing Events in Myelodysplastic Syndrome Patients with Splicing Factor Gene Mutations

Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34 blasts in myelodysplastic syndrome

165 RECURRENT MUTATIONS AS WELL AS CLONAL EVOLUTION ARE COMMON IN PATIENTS WITH LOWER-RISK MDS AND DEL(5Q) TREATED WITH LENALIDOMIDE

217 DEFINING LIKELIHOOD OF FUTURE RESPONSE IN PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE

IVA.2 Managing myelodysplastic syndromes in the frail elderly

Health-Related Quality of Life is Substantially Impaired in Lower-Risk MDS when Compared with Reference Populations and Significantly Affects Overall Survival

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

135 IN VITRO AZACITIDINE CULTURE INDUCES DNA DEMETHYLATION AND INCREASED MRNA-LEVELS IN PRIMARY MDS PROGENITOR CELLS

Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

Suchergebnisse filtern